Clinical Trials Logo

Metastatic Bone Sarcoma clinical trials

View clinical trials related to Metastatic Bone Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04877587 Withdrawn - Soft Tissue Sarcoma Clinical Trials

Gemcitabine With Ascorbate Including Adolescents

Start date: January 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this research study is to see if a high dose of ascorbate (Vitamin C), in combination with the chemotherapy drug gemcitabine, is safe and effective in adolescents with locally advanced unresectable or metastatic soft tissue and bone sarcomas

NCT ID: NCT03965234 Recruiting - Colorectal Cancer Clinical Trials

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Start date: July 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.

NCT ID: NCT02500797 Completed - Clinical trials for Metastatic Soft Tissue Sarcoma

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Start date: August 13, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with metastatic or unresectable sarcoma.